gv 1001
Vaccineexperimental
Clinical trial activity
16 trials · 30 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
13
Phase 3
5
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT01247623)
Timeline
Indications
Mechanism of action
- Telomerase reverse transcriptaseImmunity, active
TERT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gv1001
- gv1001
- gv 1001
- gv 1001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06625710 | Phase 1 | Oct 8, 2024 | Kael-GemVax Co., Ltd., Seoul National University |
| NCT06235775 | Phase 2 | Dec 12, 2023 | Kael-GemVax Co., Ltd. |
| NCT05819658 | Phase 2 | Jun 14, 2023 | Kael-GemVax Co., Ltd. |
| NCT05303701 | Phase 3 | Jan 1, 2023 | Kael-GemVax Co., Ltd. |
| NCT05189210 | Phase 2 | Oct 5, 2022 | Kael-GemVax Co., Ltd. |
| NCT03959553 | Phase 2 | Sep 1, 2019 | Kael-GemVax Co., Ltd. |
| NCT03184467 | Phase 2 | Jun 1, 2017 | Kael-GemVax Co., Ltd. |
| NCT02854072 | Phase 3 | Nov 1, 2015 | Chonbuk National University, Chonnam National University, Daegu Catholic University, Gachon University, Hanyang University, Jeju National University, Konyang University, Korea University, Pusan National University, Samsung, Seoul National University, Sungkyunkwan University, The National Cancer Center, Wonju Christian Hospital, Yonsei University |
| NCT02855892 | Phase 2 | Oct 1, 2015 | Dongguk University, Kael-GemVax Co., Ltd. |
| NCT01579188 | Phase 3 | May 1, 2012 | IQVIA, Kael-GemVax Co., Ltd. |
| NCT01342224 | Phase 1 | Jan 1, 2011 | Providence Health & Services, Robert W. Franz Cancer Center |
| NCT00509457 | N/A | Nov 1, 2006 | Norwegian University of Science and Technology, Osaka University, Sorlandet Hospital HF |
| NCT00444782 | Phase 2 | Nov 1, 2006 | Pharmexa A/S |
| NCT00425360 | Phase 3 | Sep 1, 2006 | Royal Liverpool & Broadgreen University Hospitals NHS Truts, University of London |
| NCT00358566 | Phase 3 | Jun 1, 2006 | CIRION Central Laboratory, ICON, INC Research, ORION Clinical Services, Pharmexa A/S |
| NCT01247623 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2005 | Osaka University |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kael-GemVax Co., Ltd. | For profit | 9 | 9 | 3 | 2012 |
| Osaka University | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Pharmexa A/S | For profit | 2 | 2 | 2 | 2006 |
| Seoul National University | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Chonnam National University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| CIRION Central Laboratory | For profit | 1 | 0 | 1 | 2006 |
| Daegu Catholic University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Dongguk University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Gachon University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Hanyang University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| ICON | For profit | 1 | 0 | 1 | 2006 |
| INC Research | For profit | 1 | 0 | 1 | 2006 |
| IQVIA | For profit | 1 | 0 | 1 | 2012 |
| Jeju National University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Konyang University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Norwegian University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2006 |
| ORION Clinical Services | For profit | 1 | 0 | 1 | 2006 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2011 |
30 organizations
Page 1 / 2